The need for medical care for patients with respiratory mycobacteriosis in the Russian Federation: a case study of the Central TB Research Institute: a 5-year study

Objective. To study the duration of hospitalization of patients with mycobacteriosis and their need for outpatient (dispensary) observation in the year of their initial visit to the doctor and in the following 3 years.

Materials and methods. A retrospective cohort study included 397 patients with respiratory pathology, who were diagnosed with mycobacteriosis after outpatient and/or inpatient examination at the Central TB Research Institute (CTRI) in 2020–2024. Outpatient visits to patients over 3 years of observation and 404 cases of hospitalization were analyzed. Data were obtained from medical records and processed at the Federal Center for Mycobacteriosis, organized at the CTRI. NTM was identified using genotypic methods, including standardized kits.

Results. 100% of patients required outpatient follow-up at the Central Research Institute of Traumatology and Immunology within the first year of treatment, 46.9% within the second year, and 22.2% within the third year. The average number of visits per patient was 3.1; 2.9; and 2.5, respectively. 89.8% of patients required inpatient hospitalization within the current year of treatment, with repeat hospitalization within the first year being indicated for 15% of those hospitalized. 8.6% required hospitalization in the second year and 1.6% in the third year. The number of hospitalizations for chronically ill patients was 2.6 per patient. The average length of hospital stay was 27.5 days.

1. Богуш Л.С., Тумашик С.М., Булавина Е.Н. и др. Анализ результатов клинического и микробиологического исследований пациентов с микобактериозом легких, находящихся на диспансерном учете в г. Минске // Рецепт. – 2023. – Т. 26. – № 4. – С. 464–473. https://doi.org/10.34883/PI.2023.26.4.007

2. Богуш Л.С., Рузанов Д.Ю., Давидовская Е.И., и др. Динамика распространенности микобактериоза легких в сравнении с распространенностью туберкулеза органов дыхания в Республике Беларусь в 2022–2023 гг. // Clinical infectology and parasitology. – 2025. – Vol. 14, № 1. – P. 36–44.

3. Гунтупова Л.Д., Борисов С.Е., Соловьева И.П. и др. Микобактериозы во фтизиопульмонологической практике: обзор литературы и собственный опыт // Практ. медицина. – 2011. – № 51. URL: https://cyberleninka.ru/article/n/mikobakteriozy-vo-ftiziopulmonologicheskoy-praktike-obzor-literatury-i-sobstvennyy-opyt

4. Зайцева А.С., Смирнова Т.Г., Степанян И.Э. и др. Особенности течения микобактериоза легких в зависимости от выявления возбудителя в мокроте // Вестн. Центральн. НИИ туберкулеза. – 2024. – № 1. – С. 50-59. – DOI 10.57014/2587-6678-2024-8-1-50-59

5. Клинический протокол «Диагностика и лечение микобактериоза легких (взрослое население)» / Утв. Постановлением Министерства здравоохранения Республики Беларусь 09.04.2025 № 33 https://minzdrav.gov.by/upload/dadvfiles/CProtokol/КП_Диагностика_лечение_микобактериоза_легких_в-нас_пост_МЗ_2025_33.pdf

6. Шмелев Е.И., Зайцева А.С., Макарьянц Н.Н., и др. Опыт работы с больными нетуберкулезными микобактериозами // Пульмонология. – 2022. – Т. 32. – № 1. – С. 95-102. – DOI 10.18093/0869-0189-2022-32-1-95-102

7. Corbett C., Finger P., Heiß-Neumann M. et al. Development of prevalence and incidence of non-tuberculous mycobacteria in German laboratories from 2016 to 2020 // Emerg. Microbes Infect. – 2023. – Vol. 12, № 2. – P. 2276342. doi: 10.1080/22221751.2023.2276342

8. Hamaguchi Y., Morimoto K., Mitarai S. Laboratory-based surveillance of nontuberculous mycobacterial pulmonary disease in Japan // ERJ Open Res. – 2025. – Vol. 11, № 1. – P. 00337–2024. doi 10.1183/23120541.00337-202400337-2024

9. Harada K., Quynh T.V., Yoshito N. et al. Trends in nontuberculous mycobacterial disease mortality based on 2000-2022 data from 83 countries // Int. J. Infect. Dis. – 2025. – Vol. 158. – P. 107932. https://doi.org/10.1016/j.ijid.2025.107932

10. Harada K., Hagiya H., Funahashi T. et al. Trends in the nontuberculous mycobacterial disease mortality rate in Japan: a nationwide observational study, 1997-2016 // Clin. Infect. Dis. – 2021. – Vol. 73. – P. e321–e326. doi 10.1093/cid/ciaa810

11. Lee H., Myung W., Lee E.M. et al. Mortality and prognostic factors of nontuberculous mycobacterial infection in Korea: a population-based comparative study // Clin. Infect. Dis. – 2021. – Vol. 72. – P. e610–e619. doi 10.1093/cid/ciaa1381

12. Park Y., Kim C.Y., Park M.S. et al. Age- and sex-related characteristics of the increasing trend of nontuberculous mycobacteria pulmonary disease in a tertiary hospital in South Korea from 2006 to 2016 // Korean J. Intern. Med. – 2020. – Vol. 35. – P. 1424–1431. doi: 10.3904/kjim.2019.395

13. Prevots D.R., Loddenkemper R., Sotgiu G., Migliori G.B. Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs // Eur. Respir. J. – 2017. – Vol. 49, № 4. – P. 1700374. doi: 10.1183/13993003.00374-2017

14. Takeda K., Takazono T., Mukae H. Nontuberculous mycobacterial pulmonary disease: Epidemiology, prognostic determinants, and implications for treatment decision // Resp. Invest. – 2026. – Vol. 64, № 3. – P. 101430. https://doi.org/10.1016/j.resinv.2026.101430

15. Zimenkov D., Ushtanit A. Comparative analysis of evolutionary distances using the genus Mycobacterium // Int. J. Mol. Sci. – 2025. – Vol. 26, № 21. – P. 10471. doi:10.3390/ijms262110471

16. Winthrop K.L., Marras T.K., Adjemian J. et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008-2015 // Ann. Am. Thorac. Soc. – 2020. – Vol. 17, № 2. – P. 178–185.